The $9.60 central target is calculated from eight current, individually verified analyst price targets: $4 from Leerink Partners (October 2026), $4 from Canaccord Genuity (August 2026), $5 each from Chardan Capital, Evercore ISI, LifeSci Capital, and Roth MKM (August 2026, with Roth reiterating $5 in November 2026), $14 from Piper Sandler (September 2026), and $35 from Cantor Fitzgerald (September 2026). The unrounded mean of these eight targets is approximately $9.63, and the range is unusually wide at $4 to $35.
The dispersion tells its own story. Most firms clustered near $4 to $5 after the LEVEL trial failure, while Piper Sandler and Cantor Fitzgerald kept materially higher targets on the thesis that oral levosimendan retains value in more severely ill PH-HFpEF patients. Guggenheim and William Blair both downgraded to Hold and removed targets, so they are excluded from the mean. This is not a tightly aligned analyst consensus; it is a wide range reflecting genuine disagreement about the company's remaining clinical value. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
As of the November 20, 2026 close, TENX traded at about $1.25, down from a 52-week high of $19.40. Reaching $9.60 would require an advance of roughly 670%, a very large move that would depend not on incremental progress but on a fundamental re-rating of the company's lead program. The market capitalization near $1.25 is only about $57 million, a reflection of post-trial skepticism about the pipeline's commercial prospects and the company's cash position.
The August 2026 announcement that TNX-103 (oral levosimendan) missed its primary endpoint — six-minute walk distance — and a key secondary symptom measure in the Phase 3 LEVEL trial triggered the collapse. Since then, attention has shifted to whether a subgroup of sicker patients, strategic options such as a sale or merger, and the company's imatinib-based program (TNX-201) can support value. Any path toward $9.60 would likely require new positive clinical data or a transformative corporate transaction.
Several factors could underpin a recovery. Analysts at firms such as Roth MKM and Piper Sandler continue to cite a possible opportunity in severe PH-HFpEF, where subgroup analyses suggested stronger walk-distance and biomarker signals in sicker patients. The company has also announced it is evaluating strategic alternatives, including a sale or merger, with Roth Capital Partners as financial advisor — a process that, if concluded favorably, could unlock value beyond the current share price. Insider buying has been positive, with director Declan Doogan purchasing shares in September 2026, and a Phase 3-ready pipeline beyond TNX-103 provides optionality if trials are redesigned around responder populations.
The obstacles are substantial. The LEVEL trial failure means the lead asset lacks validated pivotal efficacy, and any new trial would take time and capital the company may not have. TENX reported a GAAP net loss of about $16.7 million for the quarter ended September 30, 2026, and carries negative EPS (earnings per share). Securities class-action lawsuits alleging the company overstated TNX-103's prospects add legal overhang and potential expense. The wide analyst range — from $4 to $35 — reflects a real possibility that the surviving higher targets are optimistic relative to the data. Further dilution from a capital raise would also pressure the per-share value required to reach $9.60.
Technically, the stock is deeply broken. Shares sit far below their 50-day and 200-day moving averages after the August collapse, and the price has continued to drift lower into the low-$1.20s, testing the post-trial lows near $1.31. The prior trading range above $13 is now a distant memory, and there is little nearby technical support structure. On the upside, any durable recovery would first need to reclaim the mid-single-digit zone where post-trial analyst targets cluster ($4 to $5), making that area a meaningful resistance zone before any move toward $9.60 could be contemplated.
Analyst price targets typically reflect a roughly 12-month research horizon, though the actual horizons here vary by firm and are not uniformly disclosed. Investors should watch for updates on the strategic-alternatives process, any redesign or readout from the levosimendan program in PH-HFpEF subgroups, progress on the imatinib-based TNX-201 program, quarterly cash and burn updates, and any analyst target revisions. The December 28, 2026 lead-plaintiff deadline in the securities class actions is also a near-term event to track.
From what I see, automated signals can be particularly useful for a name like TENX that moves sharply on news. I often turn to Tickeron’s AI Daily Buy/Sell Signals to track evolving technical conditions and sentiment shifts without having to review every update manually. The platform scans thousands of stocks and ETFs in real time, which helps surface changes that might otherwise be missed in fast-moving micro-caps.
The question of whether TENX can reach $9.60 is best understood as a question about whether the company's remaining pipeline and strategic process can justify a valuation roughly seven times the current price. The central target is the mean of eight surviving analyst targets, but that mean conceals a range from $4 to $35 and omits two firms that withdrew targets altogether. The strongest supports are the severe-PH-HFpEF subgroup thesis, insider buying, and a strategic review; the principal obstacles are the failed pivotal trial, financing needs, and litigation. Because the stock has already fallen so far, even modestly positive news could drive large percentage moves — but a sustained re-rating toward $9.60 would require clinical or corporate catalysts that have not yet materialized. No outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 191 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In 73 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for TENX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 27 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TENX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.557) is normal, around the industry mean (3.596). P/E Ratio (-1.142) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of novel therapeutic products
Industry Biotechnology